Spectral AI, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $53.4M
- Price
- $1.66
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.78%
- Volume
- 262.9K
About
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
Quick stats
Shares outstanding32.2M
Computed float28.7M
Float / shares89.3%
Cash runway (months)7
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001833498
Websitehttps://www.spectral-ai.com
AI Summary
AI-generated1/25
minorbullishregulatory
Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System
Spectral AI has submitted a New Technology Add-On Payment (NTAP) application to CMS for its DeepView System, using the alternative pathway enabled by its FDA De Novo authorization and Breakthrough Device Designation.
If approved, NTAP status would generally cover approximately 65% of the technology's estimated cost, begin in October 2027, and last about three years, with a CMS determination expected in August 2027.
Management frames the application as a key step to reduce hospital adoption barriers and support the commercialization of DeepView, a multispectral imaging AI device for burn-wound healing assessment.
Red flags
- NTAP approval is uncertain and decision is not expected until August 2027 — a long approval runway
- company is still 'investing significant capital' in reimbursement pursuits, implying ongoing cash burn